These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8931997)

  • 1. Timed sequential chemotherapy for advanced acute myeloid leukemia.
    Archimbaud E; Leblond V; Fenaux P; Dombret H; Cordonnier C; Dreyfus F; Cony-Makhoul P; Tilly H; Troussard X; Auzanneau G; Thomas X; Ffrench M; Marie JP
    Hematol Cell Ther; 1996 Apr; 38(2):161-7. PubMed ID: 8931997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
    Archimbaud E; Thomas X; Leblond V; Michallet M; Fenaux P; Cordonnier C; Dreyfus F; Troussard X; Jaubert J; Travade P
    J Clin Oncol; 1995 Jan; 13(1):11-8. PubMed ID: 7799010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
    Archimbaud E; Leblond V; Michallet M; Cordonnier C; Fenaux P; Travade P; Dreyfus F; Jaubert J; Devaux Y; Fiere D
    Blood; 1991 May; 77(9):1894-900. PubMed ID: 2018832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.
    Archimbaud E; Fenaux P; Reiffers J; Cordonnier C; Leblond V; Travade P; Troussard X; Tilly H; Auzanneau G; Marie JP
    Leukemia; 1993 Mar; 7(3):372-7. PubMed ID: 8445942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
    Thomas X; Fenaux P; Dombret H; Delair S; Dreyfus F; Tilly H; Vekhoff A; Cony-Makhoul P; Leblond V; Troussard X; Cordonnier C; de Revel T; Simon M; Nicolini F; Stoppa AM; Janvier M; Bordessoule D; Rousselot P; Ffrench M; Marie JP; Archimbaud E
    Leukemia; 1999 Aug; 13(8):1214-20. PubMed ID: 10450749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial.
    He XY; Elson P; Pohlman B; Lichtin A; Hussein M; Andresen S; Kalaycio M
    BMC Cancer; 2002 May; 2():12. PubMed ID: 12019034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
    He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M
    Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
    Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
    Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
    Mandelli F; Vignetti M; Suciu S; Stasi R; Petti MC; Meloni G; Muus P; Marmont F; Marie JP; Labar B; Thomas X; Di Raimondo F; Willemze R; Liso V; Ferrara F; Baila L; Fazi P; Zittoun R; Amadori S; de Witte T
    J Clin Oncol; 2009 Nov; 27(32):5397-403. PubMed ID: 19826132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.
    Kalaycio M; Pohlman B; Elson P; Lichtin A; Hussein M; Tripp B; Andresen S
    Am J Clin Oncol; 2001 Feb; 24(1):58-63. PubMed ID: 11232951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.
    Löfgren C; Paul C; Aström M; Hast R; Hedenius M; Lerner R; Liliemark J; Nilsson I; Rödjer S; Simonsson B; Stockelberg D; Tidefelt U; Björkholm M
    Br J Haematol; 2004 Feb; 124(4):474-80. PubMed ID: 14984497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.
    McHayleh W; Sehgal R; Redner RL; Raptis A; Agha M; Natale J; Luong TM; Schlesselman JJ; Foon KA; Boyiadzis M
    Leuk Lymphoma; 2009 Nov; 50(11):1848-53. PubMed ID: 19860628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
    Wahlin A; Brinch L; Hörnsten P; Evensen SA; Oberg G; Simonsson B; Hedenus M
    Eur J Haematol; 1997 Apr; 58(4):233-40. PubMed ID: 9186533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.